

#### SCHWEGMAN ■ LUNDBERG ■ WOESSNER ■ KLUTH

PATENT, TRADEMARK & COPYRIGHT ATTORNEYS

P.O. Box 2938

Minncapolis, MN 55402

Telephone (612) 373-6900

Facsimile (612) 339-3061

April 11, 2002

FAX RECEIVED

APR 1 2 2002

(Minneapolis, Minn.)

**GROUP 1600** 

TO: Commissioner for Patents

FROM: Janet E. Embretson

Attn: Joseph F. Murphy, Ph.D. Patent Examining Corps

Washington, D.C. 20231

4:45 PM

OUR REF: 1543.002US1

Facsimile Center

TELEPHONE: (612) 373-6959

FAX NUMBER <u>(703) 305-3014</u>

\* Please deliver to Examiner Joseph F. Murphy, Ph.D. in Art Unit 1646. \*

Document(s) Transmitted: Supplemental Amendment Under 37 C.F.R. 1.116 (5 pgs.); Clean Version of Pending Claims (5 pgs.)

Total pages of this transmission, including cover letter: 11 pgs If you do NOT receive all of the pages described above, please telephone us at 612-373-6900, or fax us at 612-339-3061.

In re. Patent Application of: David J. Grainger et al.

Examiner: Joseph F. Murphy, Ph.D.

Serial No.: 09/150,813

Group Art Unit: 1646

Filed: September 11, 1998

Docket No.:\_1543.002US1

Title: COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT AN

<u>INFLAMMATORY</u> RESPONSE

Please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on the date shown below.

## **EXPEDITED PROCEDURE - EXAMINING GROUP 1646**

#### S/N 09/150,813

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

David J. Grainger et al.

Examiner: Joseph F. Murphy, Ph.D.

Serial No.:

09/150,813

Group Art Unit: 1646

Filed:

September 11, 1998

Docket: 1543.002US1

Title:

COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT AN

**INFLAMMATORY RESPONSE** 

# FAX RECEIVED

APR 1 2 2002

Box AF
Commissioner (

Commissioner for Patents Washington, D.C. 20231

**GROUP 1600** 

In response to the final Office Action mailed August 10, 2001, the Advisory Action dated January 28, 2002, and the Advisory Action dated March 28, 2002, please amend the application as follows:

#### In the Claims

Erent OK t

Please substitute the claim set in the appendix entitled "Clean Version of Pending Claims" for the previously pending claim set. The specific amendments to individual claims are detailed in the following marked up set of claims.

Please cancel claims 17, 20, 22, 34, 41-44 and 52-62 without prejudice.

Please add the following new claims:

- 63. (New) A method of preventing or inhibiting an indication associated with a chemokine-induced activity, comprising: administering to a mammal afflicted with, or at risk of, the indication an effective amount of Glu-Ile-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln (SEQ ID NO:14).
- 64. (New) A method of preventing or inhibiting an indication associated with hematopoietic cell recruitment, comprising: administering to a mammal at risk of, or afflicted with, the indication an effective amount of Glu-Ile-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln (SEQ ID NO:14).
- 65. (New) A method to modulate the chemokine-induced activity of hematopoietic cells at a